CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Remain COVID Free SSIWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug631 Contain COVID Anxiety SSI Wiki 1.00
drug2895 modification of the planned therapeutic management Wiki 1.00

Correlated MeSH Terms (7)


Name (Synonyms) Correlation
D002583 Uterine Cervical Neoplasms NIH 1.00
D014594 Uterine Neoplasms NIH 1.00
D014625 Vaginal Neoplasms NIH 1.00
D014846 Vulvar Neoplasms NIH 1.00
D010051 Ovarian Neoplasms NIH 0.71
D001943 Breast Neoplasms NIH 0.50
D009369 Neoplasms, NIH 0.22

Correlated HPO Terms (7)


Name (Synonyms) Correlation
HP:0100650 Vaginal neoplasm HPO 1.00
HP:0030416 Vulvar neoplasm HPO 1.00
HP:0030079 Cervix cancer HPO 1.00
HP:0010784 Uterine neoplasm HPO 1.00
HP:0100615 Ovarian neoplasm HPO 0.71
HP:0003002 Breast carcinoma HPO 0.50
HP:0002664 Neoplasm HPO 0.22

There is one clinical trial.

Clinical Trials


1 Project HF-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic

The goal of this study is to test whether an online, self-administered SSI designed to strengthen perceived control over anxiety in the context of the COVID-19 pandemic (Contain COVID Anxiety) increases perceived control over anxiety more than a placebo, hand-washing-plan SSI (Remain COVID Free) in a weighted-probability sample of the United States (N = 500).

NCT04459455 Anxiety Behavioral: Contain COVID Anxiety SSI Behavioral: Remain COVID Free SSI

Primary Outcomes

Description: ACQ is a 30-item questionnaire that measures an individual's level of agreement with a set of beliefs. Each item is scored on a scale from 0 (strongly disagree) to 5 (strongly agree) based on how much the statement is typical of the individual. The questionnaire measures domains of emotion control, threat control, and stress control, but only the emotion control scale (4 questions) will be used for the purposes of this study.

Measure: Change in Anxiety Control Questionnaire (ACQ) from Baseline to Immediately Post-Intervention

Time: Baseline, immediately post-intervention, 2-week follow-up

Description: The GAD-7 asks participants to rate 7 statements based on how generally anxious they have felt over the past 2 weeks. Participants rate the 7 statements on a 4 point scale ranging from 0 (Not at all) to 3 (Nearly every day). Total score ranges from 0 to 21 with higher scores representing higher generalized anxiety.

Measure: Change in Generalized Anxiety Disorder-7 (GAD-7) from Baseline to 2-week follow-up

Time: Baseline, 2-week follow-up

Description: As validated measures for social distancing intentions do not yet exist, the 3 questions used in this measure are derived from the standardized item bank provided by the Center for Disease Control. The three questions ask participants to rate how long they believe others would be willing to engage in social distancing behaviors regarding large events, public spaces, and private gatherings. Participants rate the 3 statements on a 4 point scale ranging from 1 (Less than a Month) to 4 (4 months or more). Total score ranges from 4 to 12, with a higher score indicating greater levels of intention to socially distance.

Measure: Change in Activity Social Distancing Intentions - 3 item version (SOC-D) from Baseline to immediately post-intervention

Time: Baseline, immediately post-intervention

Secondary Outcomes

Description: Derived from the CDC COVID-19 Community Survey Question Bank, participants will be asked to report whether they have been tested for COVID-19, tested positive for COVID-19, and displayed symptoms of COVID-19 in the past week. The questions also ask how the COVID-19 outbreak affected the participant in the past two weeks and if the children's schools are currently closed.

Measure: COVID-19 Related Questions

Time: Baseline

Description: The IDAS is a screening tool for depression and panic disorder that asks people to rate how they have been feeling and acting in the past two weeks. Only the dysphoria subscale will be used; the subscale consists of 10 statements which the participants rate on a 1 (Not at all) to 5 (Extremely). Total score ranges from 10 to 50 for Dysphoria.

Measure: Inventory of Depression and Anxiety Symptoms (IDAS)

Time: Baseline

Description: This brief measure asks participants to rate 7 statements measuring feelings of self-hatred on a 7-point Likert scale ranging from 1 (Not at all true for me) to 7 (Very true for me). Total score ranges from 7 to 49 with higher scores indicating higher levels of self hate.

Measure: Self Hate Scale (SHS)

Time: Baseline

Description: Two multiple choice questions developed for the purpose of the study to serve as a quality check that ensures participants comprehended the core messages of both interventions.

Measure: Comprehension Questions

Time: Immediately post-intervention

Description: The 5-item measure assesses chronic and routine unfair treatment in daily life on a scale from 1 - 5, with a total score between 5 and 25

Measure: Everyday Discrimination Scale-Short version

Time: Baseline

Description: One question designed for use in this study. Participants rate their perceived changes in levels of generalized anxiety symptoms over 2 weeks from 1 (Much less anxiety) to 5 (much more anxiety)

Measure: Perceived Changes in generalized anxiety symptoms

Time: 2-week follow-up

Description: This scale asks participants to rate 3 statements based on their intentions to engage in hand washing behaviors. Participants rate the 3 statements on a 7 point scale ranging from 1 (Strongly Agree) to 7 (Strongly Disagree). Total score ranges from 3 to 21, and will be reverse scored so a higher score indicates greater levels of intention to engage in recommended hand washing behaviors.

Measure: Activity Hand Washing Intentions - 3 item version (WASH-I)

Time: Baseline, immediately post-intervention


No related HPO nodes (Using clinical trials)